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Modified Vaccinia Virus Ankara-Based Vaccine Vectors Induce
Apoptosis in Dendritic Cells Draining from the Skin via both the
Extrinsic and Intrinsic Caspase Pathways, Preventing Efficient Antigen
Presentation
E. Guzman,a C. Cubillos-Zapata,a M. G. Cottingham,b S. C. Gilbert,b H. Prentice,a B. Charleston,a and J. C. Hopea*
Institute for Animal Health, Compton, Newbury, Berkshire, United Kingdom,a and The Jenner Institute, Oxford University, Oxford, United Kingdomb
Dendritic cells (DC) are potent antigen-presenting cells and central to the induction of immune responses following infection or
vaccination. The collection of DCmigrating from peripheral tissues by cannulation of the afferent lymphatic vessels provides
DC which can be used directly ex vivo without extensive in vitromanipulations. We have previously used bovine migrating DC
to show that recombinant human adenovirus 5 vectors efficiently transduce afferent lymphmigrating DEC-205 CD11c CD8
DC (ALDC). We have also shown that recombinant modified vaccinia virus Ankara (MVA) infects ALDC in vitro, causing down-
regulation of costimulatory molecules, apoptosis, and cell death. We now show that in the bovine system, modified vaccinia vi-
rus Ankara-induced apoptosis in DC draining from the skin occurs soon after virus binding via the caspase 8 pathway and is not
associated with viral gene expression.We also show that after virus entry, the caspase 9 pathway cascade is initiated. The magni-
tude of T cell responses to mycobacterial antigen 85A (Ag85A) expressed by recombinant MVA-infected ALDC is increased by
blocking caspase-induced apoptosis. Apoptotic bodies generated by recombinant MVA (rMVA)-Ag85A-infected ALDC and con-
taining Ag85A were phagocytosed by noninfected migrating ALDC expressing SIRP via actin-dependent phagocytosis, and
these ALDC in turn presented antigen. However, the addition of fresh ALDC toMVA-infected cultures did not improve on the
magnitude of the T cell responses; in contrast, these noninfected DC showed downregulation of major histocompatibility com-
plex class II (MHC-II), CD40, CD80, and CD86.We also observed that MVA-infected ALDC promotedmigration of DEC-205
SIRP CD21DC as well as CD4 and CD8 T cells independently of caspase activation. These in vitro studies show that in-
duction of apoptosis in DC byMVA vectors is detrimental to the subsequent induction of T cell responses.
Modified vaccinia virus Ankara (MVA)was derived fromVac-cinia virus through more than 500 blind passages in vitro in
chicken embryo fibroblasts (CEF) (50). This resulted in vaccinia
virus losing about 15% of its genome. With the exception of the
Syrian hamster cell line BHK-21, the ability ofMVA to replicate in
most mammalian primary cells and cell lines has been lost, al-
though genome replication, late-gene expression, and immature
virion formation are still able to occur, except in human blood-
derived dendritic cells (DC), in which only early viral genes are
expressed (7, 20). This makes MVA an attractive candidate for its
use as a vaccine vector to deliver recombinant proteins and induce
protective immunity. Recombinant MVA (rMVA) has been used
in various preclinical and phase I and phase II clinical trials against
a number of infectious agents or tumor-associated antigens (10,
19, 45, 55, 56).
DC are potent antigen-presenting cells capable of priming
naïve T lymphocytes and are central to the induction of immune
responses following infection or vaccination. Most systems used
to investigateDC-T cell interactions rely on the isolation ofmono-
cytes or macrophages from blood or tissues (such as spleen or
bonemarrow) (63, 71), followed bymaturationwith interleukin 4
(IL-4) and granulocyte-macrophage colony-stimulating factor
(GM-CSF) or the harvesting of tissues followed by isolation of
resident DC. Only the model of cannulation of lymphatic vessels
provides biological material, including DC derived from anatom-
ical sites used in vaccination (31, 32, 34, 49, 68). Various DC
models have been used to identify MVA-DC interactions to try to
understand rMVA-induced immunogenicity. Murine bone mar-
row-derived DC (BMDC) showed high levels of apoptosis follow-
ing infection with MVA in vitro but were still capable of inducing
antigen-specific T cell responses when these cells were transferred
to naïvemice (2). Another study showed that theseMVA-infected
BMDC were phagocytosed by uninfected DC (47); however, an-
tigen presentation by the latter was not demonstrated. More re-
cently, mouse BMDC were used to demonstrate an adjuvant ca-
pacity of MVA itself even in the presence of virus-induced
apoptosis (58). In the human system,MVAhas also been shown to
induce apoptosis in monocyte-derived DC (moDC) (11, 43).
MVA was shown to stimulate moDC as a result of infection or
using supernatants from HeLa cells infected with MVA (21) de-
spite increased apoptosis. In agreementwith data from themurine
system, human uninfected DC have been shown to take up anti-
gens from MVA-infected leukocytes (24). MVA-infected moDC
also showed impaired migration toward the lymphoid chemo-
kines CCL19 and CXCL12 (41) without affecting surface expres-
sion of the respective chemokine receptors.
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Tuberculosis is a highly infectious disease caused in humans by
Mycobacterium tuberculosis. Bovine tuberculosis is caused byMy-
cobacterium bovis, which is closely related to M. tuberculosis. M.
bovis infections pose a risk to human health and are also a major
economic problem in both the developing and the developed
world. M. bovis strain Bacille Calmette-Guerin (BCG) does not
protect against adult pulmonary tuberculosis, but it does show
protection against disease when administered in both human and
bovine neonates (13, 37). Antigen 85A (Ag85A) is a highly con-
served mycobacterial protein present in all mycobacterial species.
It has been shown to be immunodominant in both humans and
animals, and viral vectors, including MVA, expressing Ag85A
have been shown to increase immunogenicity when used in com-
bination with BCG (54, 76).
In vivo targeting of dendritic cells by vaccines is an attractive
approach for improving vaccination strategies (12). However, the
study of vaccine-DC interactions ex vivo is limited by the availabil-
ity of the relevant dendritic cells, that is, DC draining from the
headmucosae in intranasal vaccinations protocols and DC drain-
ing from the skin in subcutaneous/intradermal/intramuscular
vaccinations approaches. Afferent lymphatic DC (ALDC) repre-
sent a major population of migrating DC (14, 16, 28, 81) with
functional and phenotypic heterogeneity. We and others have de-
scribed ALDC as being high forward scatter (FSChigh) DEC-205
CD11c CD8 (17, 28, 34); within this population, subpopula-
tions expressing various levels of SIRP (CD172a), CD11a, CD26,
and CD13 have also been described (5, 28, 29, 40). These popula-
tions have been shown to interact with and stimulate T cells dif-
ferently and have differential cytokine secretion profiles (35, 40,
52, 72). A detailed understanding of in vivo populations of DC at
relevant anatomical sites is important to vaccine design.
We have recently described the differential effects of viral vec-
tors on bovine dendritic cells draining from the skin (17). We
reported that, similar tomurine BMDC and humanmoDC,MVA
induces apoptosis in DC draining from the skin. We now report
the kinetic analysis of MVA-induced apoptosis in ALDC, and in
contrast to what was observed for BMDC or moDC, this occurs
within the first few hours after infection.We also provide evidence
of the induction of both the intrinsic and the extrinsic pathways of
caspase-induced apoptosis. By blocking MVA-induced caspase
activity, we were able to increase antigen presentation to both
CD4 and CD8 T cells. We also provide evidence that apoptotic
bodies that are generated by rMVA infection, and that contain the
recombinant protein of interest, are phagocytosed by noninfected
ALDC expressing SIRP via an actin-mediated mechanism and
that these cells in turn present phagocytosed antigen to T cells.
However, the addition of fresh ALDC to MVA-infected cultures
did not increase themagnitude of the T cell responses; in contrast,
these noninfected DC showed downregulation of major histo-
compatibility complex class II (MHC-II), CD40, CD80, and
CD86. We also observed that MVA-infected ALDC promote mi-
gration of DEC-205 SIRP CD21 DC as well as CD4 and
CD8 T cells independently of caspase activation. Our model is
relevant in two ways: first, we are using dendritic cells draining
from the skin with minimal manipulation and so these are rele-
vant in intramuscular/intradermal/subcutaneous vaccination
protocols; second, we are using an animal model relevant to the
disease since cattle are a host species for mycobacterial infection.
These data provide a mechanistic description of recombinant-
MVA induced immunity using dendritic cells obtained from
anatomically relevant sites.
MATERIALS AND METHODS
Pseudoafferent lymphatic cannulation. MHC-defined, conventionally
reared 6-month-old Friesian Holstein calves (Bos taurus) from the Insti-
tute for Animal Health (IAH) herd were used for these studies. Cannula-
tions were performed essentially as previously described (34). Lymph was
collected into sterile plastic bottles containing heparin (10 U/ml), penicil-
lin, and streptomycin. The lymph collected was either used fresh or cen-
trifuged (300  g for 8 min) and resuspended in fetal calf serum (FCS)-
10% dimethyl sulfoxide (DMSO), and the cells were stored in liquid
nitrogen prior to use. Mononuclear cells were isolated from the afferent
lymph by density gradient centrifugation over Histopaque 1083 (Sigma).
Ag85A-specific T cells were obtained from MHC-defined cattle vacci-
nated subcutaneously with 106 CFU of BCG Pasteur. All T cells used were
collected at 3weeks postvaccination at the peak of the response. All animal
experiments were approved by the IAH ethics committee according to
national United Kingdom guidelines.
MAb and flow cytometry. Fluorochrome-labeled mouse anti-bo-
vine monoclonal antibodies (MAb) used in this study have been
described in detail previously (5, 38–40, 66). These were CC98-allo-
phycocyanin (APC) (anti-DEC-205), CC21-phycoerythrin (PE) (anti-
CD21), CC14-PE (anti-CD1b), andCC149-peridinin chlorophyll protein
(PerCP)/Cy5.5 (anti-SIRP), ILA-16–Alexa Fluor 680/PE (anti-CD11c),
ILA-21–PE (anti-MHC-II), ILA-88–fluorescein isothiocyanate (FITC)
(anti-MHC-I), ILA-156–PE (anti-CD40), N32/52-3–PE (anti-CD80)
ILA-159–PE (anti-CD86), CC30-APC/Cy5.5 (anti-CD4), CC63-APC/
Cy7 (anti-CD8), ILA-111–Alexa Fluor 610/PE (anti-CD25), and
CC302-PE (anti-gamma interferon [anti-IFN-]). Control MAb were
isotype- and concentration-matched anti-avian MAb (34, 80). Dead cells
were gated out using the 405-nm excitable dye LIVE/DEAD Aqua or pro-
pidium iodide (PI; Invitrogen) in accordance with the manufacturer’s
instructions. The cells were analyzed using an LSRFortessa (Becton Dick-
inson), and staining was assessed using FCS Express version 3 (DeNovo
Software). Afferent lymph DC were distinguished from other cells on the
basis of their high forward scatter (FSChigh) and high-intensity expression
of DEC-205 (28, 34). Only live single events were used for analysis.
Cell sorting. Cells were sorted into dendritic cell subpopulations by
use of a FACSAria II cell sorter (Becton Dickinson) and purities con-
firmed by flow cytometry using FACSDiva version 5 (Becton Dickinson).
T cell subsets weremagnetically separated usingmonoclonal antibody cell
sorting (MACS) technology (Miltenyi Biotech, Germany) in accordance
with themanufacturer’s instructions. Typically, the purity of the resulting
dendritic and T cell subsets was over 97% as determined by flow cytom-
etry.
Recombinant vectors. The generation of recombinant MVA express-
ing mycobacterial antigen 85A (Ag85A) has been described previously
(54). Recombinant replication-deficient human adenovirus 5 (Ad5) ex-
pressing Ag85A was generated as described previously (53). rMVA and
recombinant adenovirus 5 (rAd5) expressing green fluorescent protein
(GFP) were used as negative controls. Vectors were produced by the Jen-
ner Institute Viral Vector Core Facility University of Oxford, United
Kingdom.
UV inactivation of recombinant MVA. To inactivate viral DNA rep-
lication, recombinant MVA-Ag85A stocks were treated with 1 g/ml of
Psoralen (Calbiochem) and irradiated in a Stratalinker 1800 UV cross-
linker (Stratagene) with a 365 nm UV lamp following the method de-
scribed previously (74).
Mycobacterial antigens. Purified protein derivative from M. bovis
(PPD-B) was obtained from the tuberculin production unit at the Veter-
inary Laboratories Agency (VLA), Weybridge, United Kingdom, and was
used at 10 g/ml. Recombinant antigen 85A (Ag85A) was obtained from
Lionex GmbH (Germany) and used at 2 g/ml in all assays.
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Infection of afferent lymph cells. Afferent lymph cells were cultured
in tissue culture medium (TCM; Iscove’s modified Dulbecco’s medium
[IMDM] containing 10% FCS [Autogen Bioclear, United Kingdom],
105M2--mercaptoethanol [Sigma-Aldrich, Poole,UnitedKingdom]),
with the recombinant viruses using optimal multiplicities of infection
(MOI) described previously (17).
Apoptosis assays.Cells were resuspended to 1 106 cells per 0.1ml in
annexin V staining buffer (apoptosis kit; R&D Systems, Minneapolis,
MN) and stained with annexin V-Pacific Blue and propidium iodide or
LIVE/DEAD Aqua (Invitrogen) in accordance with the manufacturer’s
instructions and analyzed by flow cytometry.
Western blot analysis.To detect Ag85A expression in rMVA-infected
ALDC or phagocytosed apoptotic bodies, flow-sorted cells were lysed in
cell lysis buffer containing 0.5% NP-40, 50 mM NaCl2, 20 mM Tris-HCl
(pH 7.5). Fifty microliters of cell lysate was then mixed with equal vol-
umes of sodiumdodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
loading buffer (50 mmol/liter Tris-Cl [pH 6.8], 100 mmol/liter dithio-
threitol, 2% sodium dodecyl sulfate, 0.1% bromophenol blue, and 10%
glycerol) and denatured by boiling for 5 min. Samples were separated on
a 12% sodium dodecyl sulfate-polyacrylamide gel, transferred to a nitro-
cellulose membrane, blocked with a 2% dry milk solution, and probed
with either mouse anti-Ag85A monoclonal antibody clone TD-17 at a
concentration of 2 g/ml (a kind gift from K. Huygen, Pasteur Institute,
Brussels, Belgium) ormouse anti--actin (Abcam). After extensive wash-
ing with phosphate-buffered saline (PBS) containing 0.5% Tween 20
(PBS-T), the membrane was incubated with a rabbit anti-mouse horse-
radish peroxidase-conjugated secondary antibody (Dako) at a final con-
centration of 5 g/ml. After extensive washing with PBS-T, Ag85A was
detected by luminescence using ECL Advance (Amersham) and autora-
diography films (Amersham Hyperfilm ECL) were exposed for 1 min.
Inhibition of caspases. Specific and pan-specific caspase inhibitors
were obtained from Merck Biosciences (Darmstadt, Germany) and used
in accordance with themanufacturer’s instructions. Caspase 3 inhibitor II
Z-DEV-FMK, caspase 8 inhibitor II Z-IETD-FMK, caspase 9 inhibitor I
Z-LEHD-FMK, and general caspase inhibitor Z-VAD-FMKwere used at a
1 nM final concentration in accordance with the manufacturer’s instruc-
tions. The negative control Z-FA-FMV and a DMSO control were used in
all inhibition assays.
Caspase activity ELISA. ALDC (1  106) were infected with rMVA-
Ag85A using an MOI of 3 PFU/cell and lysed after various infectious
periods using lysis buffer containing 0.5% NP-40, 50 mM NaCl2, 0.1%
SDS in PBS. Caspase activity was thenmeasured using either the caspase 8
or the caspase 9 activity enzyme-linked immunosorbent assay (ELISA;
R&D Systems) in accordance with the manufacturer’s instructions in 98-
well flat-bottomed plates (Costar). A550 was measured using a FLUOstar
Optima microplate reader (BMG Labtech, Germany).
Phagocytosis assays. Fluorescence-activated cell sorting (FACS)-
sorted DC were labeled with the green-fluorescing dye PKH-67 (Sigma,
United Kingdom) in accordance with the manufacturer’s instructions.
DCwere then infected with rMVA-Ag85A using anMOI of 3 PFU/cell for
60 min at 37°C. The cells were washed twice with PBS, resuspended in
TCM, and cultured overnight in 12-well plates (Costar). The following
day, autologous FACS-sorted DC were labeled with the red-fluorescing
dye PKH-46 (Sigma, United Kingdom) and added to MVA-infected cells
at a ratio of 1:1. Cocultures were then incubated at 37°C or 4°C for 4 h to
allow phagocytosis to occur, harvested, and analyzed by flow cytometry.
Inhibition of phagocytosis. To identify the mechanism of phagocy-
tosis of rMVA-induced apoptotic bodies by ALDC, phagocytosis assays
were set up as described above in the presence of the following inhibitors,
which have been shown to block phagocytosis: cytochalasin D (10 M;
actin dependent [65]), fillipin (5g/ml; caveolae dependent [64]), chlor-
prozamine (10 g/ml; prevents clathrin-coated-pit formation [78]),
methyl--cyclodextrin (10 mM; cholesterol dependent [75]), and
amiloride (10 mM; blocks Na [79] and therefore macropinocytosis
[66]). DMSOwas used as a diluent control, and PBSwas used as a negative
control. All chemicals were obtained through Sigma-Aldrich (Poole,
United Kingdom).
Confocal microscopy. FACS-sorted DC (FSChigh DEC-205) either
freshly isolated or harvested from a phagocytosis assay were cultured on
collagen-treated coverslips (Sigma) for 6 h to allow adhesion of cells to the
coverslips. The cells were fixed with acetone at20°C for 3 min, washed
twice with PBS, permeabilized with 3% paraformaldehyde for 20 min,
washed twice with PBS, and stained with DAPI (4=,6-diamidino-2-phe-
nylindole; Invitrogen) in accordance with the manufacturer’s instruc-
tions. Cells weremounted ontomicroscope slides usingVectaShield (Vec-
tor Laboratories, United Kingdom) and observed using a Leica SP5
confocal microscope.
Migration assays. All assays were performed in triplicate. Three hun-
dred microliters of culture supernatants from an overnight infection of
ALDC with MVA-Ag85A was added to a 24-well plate (Corning), fol-
lowed by addition of 8-mTranswell inserts (Corning). ALDC (1 105)
in a 100-l total volume were then added to the inside compartment of
the Transwell insert and incubated for 4 h at 37°C. The cells that
migrated toward the lower compartment were harvested and analyzed
by flow cytometry. Migration index was calculated as the mean num-
ber of cells migrating toward the medium from MVA-infected DC
divided by the mean number of cells migrating toward the medium
from noninfected DC.
Antigen presentation and T cell responses. Populations of dendritic
cells were FACS purified, washed five times with PBS, and incubated with
recombinant vectors, recombinant Ag85A, PPD-B, or TCM for 90 min at
37°C in a 96-well U-bottomed plate (Costar). The cells were washed twice
with PBS, resuspended in TCM, and mixed with either peripheral blood
mononuclear cells (PBMC) or MACS-sorted CD4 T and CD8 T cells
from MHC-matched BCG-vaccinated animals at a ratio of 1 DC to 10 T
cells in a final volume of 200l (48). For detection of IFN- expression by
an enzyme-linked immunospot (ELISPOT) assay, the cells were trans-
ferred to nitrocellulose-backed 96-well MultiScreen hemagglutinin (HA)
plates (Millipore, Bedford, MA) which had been coated with 100 l of 8
g/ml anti-bovine IFN-MAb CC330. The cells were incubated for 24 h
at 37°C, and the assay continued as previously described (36). In some
assays, proliferation was assessed by labeling cells with carboxyfluorescein
diacetate succinimydyl ester (CFDA-SE) as previously described (17). The
results are shown as percent proliferation, determined as the percentage of
CFSELOW cells.
Statistical analyses. Data are presented as means  standard devia-
tions, and groups were compared using one-way analysis of variance
(ANOVA) and pairwise comparison. Geographical and descriptive statis-
tics as well as line and bar graphs were generated using GraphPad Prism
version 5.04 for PC.
RESULTS
MVA-expressed Ag85A is not efficiently presented by ALDC.
Since poxvirus-based vaccines are normally delivered by intrader-
mal or subcutaneous administration or by scarification of the
skin, the model of cannulation of pseudoafferent lymphatic ves-
sels is relevant in providing biological material for in vitro studies
of cells migrating from the skin toward lymph nodes. To test the
hypothesis that antigens expressed by recombinant vectors are
efficiently presented by afferent lymph dendritic cells (ALDC), we
infected ALDC in vitro with recombinant MVA (rMVA) or re-
combinant adenovirus 5 (rAd5) expressingmycobacterial antigen
85A (Ag85A) or loaded cells with recombinant Ag85A or PPD-B
to stimulate T cells from BCG-vaccinated animals. We have pre-
viously shown that by infecting ALDCwithMVA-GFP at anMOI
of 1 to 5 PFU/cell, the number of GFP cells is similar to that of
Ad5-GFP infected ALDC at anMOI of 100 IU/cell (17).We there-
fore used rMVA-Ag85A at anMOI of 3 PFU/cell and rAd5-Ag85A
at 100 IU/cell. ALDC effectively stimulated IFN- secretion from
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T lymphocytes following pulsing with rAg85A or PPD-B or when
transduced with rAd5-Ag85A. Although ALDC infected with
rMVA-Ag85A induced antigen-specific IFN- secretion higher
than rMVA expressing GFP (P	 0.0093; data not shown) or cells
cultured with medium alone (P 	 0.0091), these levels were sig-
nificantly lower than those for rAd5-Ag85A (P	 0.0083), rAg85A
(P	 0.0078), and PPD-B (P	 0.0052) (Fig. 1).
ALDC become apoptotic 30 min after infection with recom-
binant MVA. Upon microscopic analysis of MVA-infected
ALDC, the cells appeared rounded with membrane blebbing, in-
dicative of apoptosis (data not shown). To confirm that MVA-
infected ALDC became apoptotic, we infected freshly isolated
ALDC with MVA at an MOI of 3 and stained the cells using an-
nexin V and LIVE/DEAD stain before analysis by flow cytometry
at various time points (Fig. 2). As early as 30 min postinfection,
20% of ALDC were annexin V positive (Fig. 2B), and at 24 h
postinfection, over 50% of the cells were LIVE/DEAD positive,
indicating significant levels of cell death (Fig. 2E). Samples cul-
tured with UV-inactivated virus showed an initial increase in
number of annexinV cells, but this frequency remained constant
(Fig. 2E). To confirm that the effect of cell death was due to virus
infection, ALDCwere infectedwith rMVAexpressingGFP orwith
recombinant vectorwhich had beenUV inactivated. Compared to
the level formock-infected ALDC (Fig. 2F), Fig. 2G shows that the
majority of LIVE/DEAD cells wereGFP, and Fig. 2H shows that
GFP expression and cell death can be blocked by UV inactivation.
Both the intrinsic and the extrinsic caspase pathways are in-
volved in MVA-induced apoptosis of ALDC. Apoptosis can be
activated via two independent caspase pathways, the extrinsic
pathway characterized by the activation of caspase 8 and the in-
trinsic pathway characterized by the activation of caspase 9. To
identify if infection by rMVA induced caspase-mediated apopto-
sis, we infected ALDC with rMVA-A85A or UV-inactivated
rMVA-Ag85A and collected cells at various time points. Caspase 8
and caspase 9 activities were measured by ELISA (Fig. 3). Caspase
8 activity was detected in ALDC infected with rMVA-Ag85A as
soon as 2 h following infection and was significantly (P	 0.0021)
higher than the level for the mock-infected control (Fig. 3A). At
that time point, similar caspase 8 activity in ALDC infected with
UV-inactivated virus (P 	 0.8951) was measured. At 6 hours
postinfection, caspase 8 activity in cells treated with both rMVA
and UV-inactivated rMVAwas not significant (P	 0.6201) com-
pared to the level for mock-infected cells (Fig. 3A). In contrast,
increased caspase 9 activity was not significant until 12 h postin-
fection (P 	 0.0039) in ALDC infected with rMVA-Ag85A (Fig.
3B). Caspase 9 activity in cells cultured with UV-inactivated virus
remained similar to that observed in uninfected cells (P	 0.1089).
ALDCwere then infectedwith rMVA-Ag85A in the presence of
apoptosis inhibitors. Preliminary results showed that by using a
caspase 3 inhibitor or a nonspecific caspase inhibitor cocktail, the
frequency of MVA-induced apoptosis was reduced (data not
shown) compared to the level for the caspase inhibitor negative
control. We therefore used a caspase 8 inhibitor to block the ex-
trinsic pathway and a caspase 9 inhibitor to block the intrinsic
pathway.
When ALDC were infected in the presence of a caspase 8 in-
hibitor, MVA-induced apoptosis was delayed compared to that in
cells infected in the absence of caspase inhibitors (Fig. 3C), with
significant differences observed at 2 (P 	 0.0402) and 4 (P 	
0.0033) h postinfection. No significant differences in apoptosis
between MVA-infected ALDC in the presence or absence of
caspase inhibitors (P	 0.1256) were observed at 6 h postinfection
or later (Fig. 3C). In contrast, ALDC infected with MVA in the
presence of caspase 9 inhibitor rapidly became apoptotic and died,
and there were no significant differences between cells in the pres-
ence or absence of caspase 9 inhibitors at these early time points
(P 	 0.5303). At 6 h postinfection, the frequency of annexin V
ALDC infected with MVA in the presence of caspase 9 inhibitor
was significantly different (P 	 0.0247) from that of MVA-in-
fected ALDC in the absence of caspase inhibitors. There was a
reduction in the number of annexin V cells in the later sample
because these cells became annexin V PI. To confirm that both
caspase pathways were involved in MVA-induced apoptosis, we
infected ALDC with rMVA in the presence of both caspase 8 and
caspase 9 inhibitors. The combination of both inhibitors delayed
the expression of annexin V for 12 h in MVA-infected cells com-
pared to that in cells infected in the absence of inhibitors (P 	
0.0174), and at 24 h postinfection, the use of inhibitors did not
have an effect on the number of annexin V cells (P 	 0.1741)
(Fig. 3E).
BlockingMVA-induced caspases in ALDC improves antigen
presentation. To test the hypothesis that preventing or delaying
MVA-induced apoptosis improves antigen presentation, ALDC
collected from animals of known MHC haplotypes were infected
with rMVA-Ag85A in the presence or absence of caspase inhibi-
tors and these were then used to stimulate T cells from MHC-
matched BCG-vaccinated animals. Following infection with
rMVA-Ag85A, ALDC were able to induce a low frequency of ex-
pression of IFN- that was significantly lower than that induced
by ALDC transduced with Ad5-85A or PPD-B as shown previ-
ously (Fig. 1). However, the addition of caspase inhibitors during
MVA infection significantly increased (P	 0.0058) the capacity to
induce secretion of IFN- by PBMCcompared to the level for cells
FIG 1 MVA-expressed Ag85A is not efficiently presented by ALDC. FACS-
sorted FSChigh DEC-205 cells fromMHC-defined animals were infected with
recombinant viruses expressing Ag85A or loaded with rAg85A (2 g/ml) or
PPD-B (20g/ml) and were used as antigen-presenting cells. IFN- responses
by PBMC from MHC-matched animals (n	 8) were measured by ELISPOT
assay. Bars represent mean numbers of spot-forming units (SFU) per million
PBMC. Error bars represent standard deviations of results from triplicate
wells.
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FIG 2 rMVA induces apoptosis in ALDC shortly after infection. ALDCwere infected with rMVA-Ag85A orUV-inactivated virus at 4°C for 60min to allow virus
attachment; excess virus was removed by extensive washing, and cells were cultured at 37°C. Aliquots were then harvested at various time points, and apoptosis
was measured using annexin V and LIVE/DEAD stain by flow cytometry. (A to D) Annexin V-LIVE/DEAD dot plots showing apoptosis before infection and at
30min, 2 h, and 24 h postinfectionwithin gatedDEC205hi ALDC. (E) Line graph showing the frequency of apoptotic ALDC after rMVA infection (black squares)
compared with UV-inactivated rMVA (white diamonds) and mock-infected cells (black circles). Points indicate means of results from cells from 5 individual
animals analyzed in duplicate, and error bars indicate standard deviations. (F to H) Dot plots showing GFP expression inMVA-infected cells. ALDCwere mock
infected (F) or infected with rMVA-GFP (G) or with UV-inactivated rMVA-GFP (H) as described above. Cell death and GFP expression in gated DEC205hi
ALDC were measured after 6 h by flow cytometry. Plots are representative of five individual experiments.
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cultured in the absence of caspase inhibitors (Fig. 4A). The num-
ber of antigen-specific spot-forming units (SFU) in those samples
containing rMVA plus inhibitors increased such that these sam-
ples were comparable to samples containing rAd5-Ag85 (P 	
0.5021) andPPD-B (P	 0.2913).We also assessed the stimulation
of T lymphocyte proliferation (Fig. 4B and C). Low-level stimula-
tion of CD4 and CD8 proliferation was observed when ALDC
were infected with MVA-Ag85A compared to the level for ALDC
transduced with Ad5-Ag85A (P 	 0.0051 and P 	 0.0041 for
CD4 andCD8, respectively) or pulsedwith PPD-B (P	 0.0017
and P 	 0.0011, respectively). However, significantly enhanced
stimulation was observed when ALDC were infected with MVA-
Ag85A in the presence of caspase inhibitors such that these re-
sponses were comparable to those for rAd5-Ag85A (P	 0.8323)
andPPD-B (P	 0.8979). To confirm that apoptosis inhibitors did
not have a nonspecific effect on antigen presentation, we mea-
sured Ag85A-specific IFN- release responses by ELISPOT assay
using ALDC infected with rMVA-Ag85A, transduced with rAd5-
Ag85A, or loaded with rAg85A, all in the presence or absence of
inhibitors as antigen-presenting cells. Figure 4D shows that treat-
ment with caspase inhibitors has a significant effect (P	 0.0058)
in antigen presentation only in those samples infectedwith rMVA.
Ag85A-specific responses obtained using rMVA-GFPwere similar
to those in mock-infected cells (data not shown).
Apoptotic bodies derived from MVA-infected ALDC are
phagocytosed by noninfected ALDC. We demonstrated that
MVA induced apoptosis and cell death in ALDC rapidly after in-
fection in vitro and that this significantly hindered direct antigen
presentation. However, MVA has been shown to be an effective
vaccine vector especially in prime-boost vaccination protocols. In
light of this dichotomy, we investigated potential mechanisms for
antigen presentation. MVA-infected ALDC were labeled with
PKH-67 (to label cellular membranes green) and cultured over-
night, inducing apoptosis. Uninfected PKH-46 (red)-labeled
FIG 3 Both the extrinsic and the intrinsic caspase pathways are involved in apoptosis in MVA-infected ALDC. (A and B) ALDC (1 106) were infected with
rMVA-Ag85A orUV-inactivated rMVA-Ag85A (MOI	 3) at 4°C for 60min to allow virus attachment; excess virus was removed by extensive washing, and cells
were cultured at 37°C. Aliquots were collected at various time points and cell lysates tested for caspase 8 (A) and caspase 9 (B) activity by ELISA. (C to E) ALDC
(1 106) were infected with rMVA-Ag85A (MOI	 3) as described above in the presence of caspase 8 inhibitor (C), caspase 9 inhibitor (D), or both (E). Graphs
represent means of results from cells from 5 different animals analyzed in duplicate. Error bars indicate standard deviations.
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ALDC were then added and cocultured with MVA-infected cells
for 4 h at 37°C or 4°C prior to fluorescence measurement by flow
cytometry (Fig. 5). Both MVA-infected and control ALDC were
efficiently labeled (Fig. 5A and B). Coculture of MVA infected
ALDC with uninfected ALDC at 37°C resulted in a significant
number (
20%) of double-red-green-positive cells (Fig. 5D), in-
dicating uptake of apoptotic cells by the uninfectedALDC.At 4°C,
fewer than 10% of ALDC became double positive (Fig. 5C). To
gain further insight, we FACS purified the three populations rep-
resented in Fig. 5D and detected Ag85A-containing cells byWest-
ern blot analysis (Fig. 5E). ALDC infected with rMVA-Ag85A ex-
pressed the Ag85A (lower right) and, following coculture rAg85A,
was also expressed in ALDC that were not exposed directly to
MVA-Ag85A (upper right), confirming that the uninfectedALDC
have taken up material from the MVA-infected cells. We also an-
alyzed the double-positive (upper right) population by confocal
microscopy (Fig. 6). Apoptotic bodies fromMVA-infected ALDC
(green dots) were found within noninfected ALDC.
To identify the mechanism by which apoptotic bodies were
taken up by ALDC, phagocytosis inhibitors were added to the
cultures (Fig. 7A). The frequency of apoptotic body uptake by
ALDC as described above was significantly reduced in the pres-
ence of cytochalasin D (P 	 0.0337), indicating that this process
was actin mediated. However, no significant differences were ob-
served with other inhibitors (chlorprozamine [clarthin depen-
dent], fillipin [caveolae dependent], amiloride [Na channel
blocker], and methyl--cyclodextrin [cholesterol dependent]).
We determined whether DC which had taken up antigen-con-
taining apoptotic bodies from MVA-infected DC could present
Ag85A to T lymphocytes making the recombinant antigen avail-
able within a nonapoptotic DC for cross-presentation. We in-
fected ALDC with rMVA-Ag85A at an MOI of 3 and after an
FIG 4 Blocking MVA-induced apoptosis improves antigen presentation in vitro. ALDC were infected with rMVA-Ag85A in the presence or absence of caspase
inhibitor cocktail or with rAd5-Ag85A (as described in Materials and Methods), were loaded with mycobacterial PPD-B (20 g/ml), or were mock infected.
PBMC fromMHC-matched BCG-vaccinated cattle (n	 10) were then added to ALDC cultures. IFN- responses were measured by ELISPOT assay (A and D),
and CD4 (B) or CD8 (C) T cell proliferation was measured by CFDA-SE dilution by flow cytometry. Error bars indicate standard deviations of results from
samples tested in duplicate.
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overnight culture added an equal number of freshly isolated au-
tologous ALDC and MHC-matched T cells. Phagocytosis inhibi-
tors or controls were also added. ALDCwhich had taken up apop-
totic bodies were able to present antigen and stimulate IFN-
secretion (Fig. 7B); this was significantly reduced (P	 0.0042) in
the presence of cytochalasin D (Fig. 7B). Similarly, ALDC were
able to promote proliferation of CD4 (Fig. 7C) and CD8T cells
(Fig. 7D), and this was significantly blocked by cytochalasin D
(P 	 0.0039 and P 	 0.0041, respectively). To confirm that cy-
tochalasin D did not have a nonspecific effect on antigen presen-
tation, we infectedALDCwith rMVA-Ag85A at anMOI of 3 in the
presence of cytochalasin D, fillipin, DMSO, and PBS and mea-
sured T cell activation by ELISPOT assay. All four treatments
showed similar IFN- responses (data not shown).
MVA infection of ALDC downregulates costimulatory mol-
ecules in noninfected cells. The magnitudes of IFN- responses
to Ag85A in experiments where ALDC were infected with rMVA
(Fig. 1 and 4A) and in experiments where autologous noninfected
ALDC were added to cells already infected with rMVA (Fig. 7B)
were similar (P 	 0.1580). To investigate why these responses
were still low compared to responses obtained using rAd5-Ag85A,
we infected 1  106 ALDC with a suboptimal concentration of
rMVA-Ag85A (0.5 PFU/cell) for 60 min and washed them exten-
sively to remove excess virus. We then added the same number of
uninfected autologousALDC.After an overnight culture, wemea-
sured cell death by PI incorporation and cell surface expression of
CD40, CD80, CD86, MHC class I, and MHC class II by flow cy-
tometry. Figure 8 shows the numbers and mean fluorescence in-
tensities (MFI) of these molecules in mock-infected cells (Fig. 8A,
D, G, J, and M). CD40, CD80, CD86, and MHC-II were down-
regulated in PI ALDC, but interestingly, these were also down-
regulated in PIALDC(Fig. 8B, E,H, andN).MHCclass Iwas not
downregulated in PI ALDC, but in 5% of PI ALDC, this was
downregulated (Fig. 8K). Antibody isotype controls were used to
demonstrate that these were not binding nonspecifically to PI
cells (Fig. 8C, F, I, L, andO). To confirm that there was no residual
virus in the system that could account for the observed effects on
bystander cells, we infected ALDC with rMVA-GFP and washed
them extensively as described above. Cells were then cocultured
along with CEF, and GFP expression was assessed 16 h later by
flow cytometry. Figure 8P shows that after the washing steps most
of the inoculum is removed and fewer than 0.80% of permissive
CEF cells show GFP expression compared to the level for CEF
directly infected with rMVA-GFP. These results were also con-
firmed by fluorescence microscopy (data not shown).
MVA-infected ALDC promote chemoattraction of nonin-
fected ALDC and T cells. To identify whether MVA-infected
ALDC secreted chemokines which attracted noninfected cells,
which could then take up apoptosing cells for antigen presenta-
tion, we used a trans-well assay to measure migration of both DC
and T cells toward supernatants of MVA-infected ALDC. Den-
dritic cell migration levels were significantly higher in those sam-
ples containing supernatants from cells infected for 24 h than in
samples containing supernatants from cells infected for 4 h (Fig.
9A). Similarly, T cell migration toward supernatants from MVA-
infected DC for 24 h was at a significantly higher level thanmigra-
tion toward supernatants frommock-infected ALDC but was not
statistically significant in samples containing supernatants from
DC infected for only 4 h (Fig. 9B). Interestingly,more than 95%of
the migrating ALDC expressed SIRP, and two-thirds of these
were CD1b CD21 (Fig. 9C and D and data not shown).
DISCUSSION
Recombinant modified vaccinia virus Ankara (rMVA) has been
and is being used in clinical trials of novel vaccines to induce
immunity against tuberculosis (54), HIV infection (3, 59), and
influenza (44), to name but three examples, with promising re-
sults. rMVA has been reported to induce antigen-specific immu-
noglobulins and CD8T cell responses in humans as well as other
species (1, 8, 15, 23), and the predominant mechanism by which
the recombinant protein is presented to B and T cells in vivo is
thought to be cross-presentation (57). The main role of dendritic
cells is the presentation of antigen to T cells, in particular priming
of naïve T cells within the lymph node (60, 73).Most systems used
to investigateDC-T cell interactions rely on the isolation ofmono-
cytes or macrophages from blood or tissues (such as spleen or
bone marrow) (63, 71) followed by maturation with IL-4 and
GM-CSF or the harvesting of tissues followed by isolation of res-
ident DC. Dendritic cells in the epithelia are thought to take up
antigen by pinocytosis, macropinocytosis, or receptor-mediated
endocytosis (6, 40, 51). Peripheral dendritic cells then migrate via
the afferent lymphatic ducts to the draining lymph nodes, losing
FIG 5 Apoptotic bodies fromMVA-infected cells are phagocytized by nonin-
fected DC. PKH-67-labeled ALDC were infected with rMVA-Ag85A (MOI	
3) as described in Materials and Methods and cultured overnight at 37°C.
PKH-46-labeled autologous ALDC were then added to the culture, incubated
at either 4°C or 37°C for 4 h, and analyzed by flow cytometry. (A) PKH-46-
labeled (red) cells. (B) PKH-67-labeled (green) cells. (C) Mixed culture incu-
bated at 4°C. (D) Mixed culture incubated at 37°C. Dot plots shown are gated
on FSChigh MHCII CD11c DEC205 live single events and are representa-
tive of experiments performed using cells from 10 individual animals. (E)
Western blot (representative of 3 independent experiments) showing the pres-
ence of Ag85A and -actin in FACS-sorted ALDC from panel D. LR, lower
right; UR, upper right; and UL, upper left.
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their ability to take up antigen but becoming very potent antigen-
presenting cells. This model is challenged by the identification of
dendritic cells from afferent lymph; these afferent lymph-veiled
cells (51), which migrate from peripheral tissues, are able to pro-
cess antigen and are potent stimulators of resting and naïve T cells.
We have previously shown that dendritic cells draining from
the skin and collected by cannulation of pseudoafferent lymphatic
vessels (34) are FSChigh DEC-205 CD11c CD8 cells. Within
this population, two major subpopulations can be identified,
those cells expressing high levels of SIRP and those expressing
low levels or no detectable SIRP (40, 51). Langerhans cells rep-
resent about 5% of the total number of migrating lymphatic DC,
and all of these express SIRP (33). Although both populations
express high levels of costimulatory molecules (CD40, CD80, and
CD86) and MHC class II, it is evident that only the SIRP cells
present antigen efficiently (40).
Tuberculosis is an infectious disease caused by Mycobacteria
spp. in both humans and cattle, with important health and eco-
nomic consequences. The use of heterologous prime-boost strat-
egies has led to the development of recombinant vaccines to im-
prove immunogenicity in humans and animals, and rMVA
expressing the mycobacterial antigen 85A is a promising candi-
date for boosting T cell responses following priming with BCG
(77, 83). We have recently described that dendritic cells draining
from the skin and expressing SIRP are efficiently targeted by
recombinant vectors (17) and that rMVA induces apoptosis and
cell death. We now describe the kinetics and mechanism of
rMVA-induced apoptosis in DC draining from the skin. Our
model is relevant in two ways: first, we are using dendritic cells
draining from the skin with minimal manipulation, and so these
are relevant in intramuscular/intradermal/subcutaneous vaccina-
tion protocols; second, we are using an animal model relevant to
the disease since cattle are a host species for mycobacterial infec-
tion. While performing pilot experiments, we found that of the
cells present in the afferent lymph, only DC were targeted by
rMVA-GFP. In contrast, primary bovine skin fibroblasts showed
10% infection when anMOI of 100 PFU/cell of rMVA-GFPwas
used (data not shown), suggesting that DC are the primary infec-
tion target upon MVA injection. However, these data need to be
confirmed in vivo. It is clear that even at lowMOI, ALDC infected
with rMVA are less efficient at presenting Ag85A compared to
ALDC transduced with rAd5-Ag85A or pulsed with recombinant
Ag85A protein (Fig. 1). Our data suggest that this is due to a very
rapid induction of apoptosis (Fig. 2), evident in as little as 2 h
postinfection, which prevents efficient rAg85A expression in the
MVA-infected cells. Furthermore,MHC class I and II levels on the
cell surface are concomitantly reduced. Although MVA-induced
apoptosis has been described before in various DC cell models (2,
11, 43, 47), to our knowledge this is the first report showing the
interaction of DC draining from the skin and MVA. Our data
show that MVA-induced apoptosis occurs much faster than pre-
viously thought; thismay be biologically important and highlights
the need to use cells from anatomically relevant sites to under-
stand the generation of immune responses.
We also show that MVA induces apoptosis via two caspase
pathways, the extrinsic pathway characterized by the activation of
caspase 8 and the intrinsic pathway characterized by the activation
of caspase 9. In a model using human monocyte-derived DC,
FIG 6 Apoptotic bodies fromMVA-infected DC are taken up by noninfected ALDC. PKH-67-labeled ALDC (green) were infected with rMVA-Ag85A (MOI	
3) as described in Materials andMethods and cultured overnight at 37°C. Unlabeled autologous ALDC were added to the culture and incubated at 37°C for 4 h.
Cells were stained, and FSChighMHCIICD11cDEC-205 live single events positive for PKH-67were FACS sorted, washed twice,mounted on a coverslip, and
analyzed by confocal microscopy. Panel A shows DAPI; panel B shows PKH-67-labeled apoptotic bodies; panel C red shows DEC-205; panel D shows a merge
of all three.
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Brandler and colleagues showed that UV-inactivated rMVA-HIV
did not induce apoptosis (4). However, here we show that caspase
8 is activated following virus binding or entry, demonstrated by
the increase in caspase 8 activity in ALDC cultured with UV-inac-
tivated MVA, initiating the caspase cascade. This suggests that an
MVA-expressed pathogen-associated molecular pattern (PAMP)
is responsible for the initiation of the extrinsic caspase pathway.
Following virus entry and after 4 h postinfection, the caspase 9
cascade is initiated, promoting the expression of annexin V on the
cell surface (Fig. 3), and both of these pathways can be blocked
independently using caspase-specific inhibitors.We hypothesized
that by blocking MVA-induced apoptosis, the antigen presenta-
tion capabilities of the rMVA-infected DC would improve. We
showed increased antigen presentation to both CD4 and CD8
T cells, demonstrated by increased IFN- production and greater
Ag85A-specific proliferation in samples containing caspase inhib-
itors compared to the levels in samples containing rMVA-Ag85A
alone (Fig. 4). This suggests that under these conditions, direct
presentation is responsible for T cell activation. Poxviruses are
known to encode several apoptosis-inhibiting gene products (18,
22, 30, 42, 82), but the activity of these proteins inmammalianDC
systems and their effect on recombinant poxvirus vaccination
strategies are yet to be shown. Furthermore, many of these pro-
teins are missing in the attenuated MVA strain (25). We are cur-
rently investigating vaccination efficacy and potency of recombi-
nant MVA mutants that have a delayed capacity to induce
apoptosis.
Because themagnitudes of IFN- responses toAg85A in exper-
iments where ALDCwere infectedwith rMVA and in experiments
where autologous noninfected ALDC were added to cells already
infected with rMVA were not significantly different, we analyzed
the levels of MHC class I, MHC class II, and costimulatory mole-
cules in infected and cocultured noninfected DC. We have previ-
ously shown that ex vivo ALDC express high levels of these mole-
cules and that they are downregulated following infection with
rMVA (17). It is unclear how this downregulation occurs, but our
experiments indicate that the expression of early viral proteins is
required prior to the observed downregulation. We are currently
investigating the effects ofMVA protein expression on the surface
expression ofMHC and costimulatorymolecules on ALDC.Here,
FIG 7 Uptake of apoptotic bodies by ALDC is by actin-mediated phagocytosis. (A) PKH-67-labeled ALDC were infected with rMVA-Ag85A (MOI 	 3) as
described in Materials and Methods. PKH-46-labeled autologous ALDC were added to the culture, incubated at 37°C for 4 h in the presence of the indicated
inhibitors, and analyzed by flow cytometry. Cells were gated on FSChighMHCIICD11cDEC-205 live single events. Bars represent means (n	 10) of results
from events present in the upper right (UR) quadrant as shown in Fig. 5 (double positive for PKH-67 and PKH-46). Error bars indicate standard deviations. (B,
C, andD)ALDCwere infectedwith rMVA-Ag85A (MOI	 3), and after an overnight culture, autologous ALDCwere added. Antigen presentationwasmeasured
by ELISPOT assay (B) or T cell proliferation by flow cytometry (C and D). Bars represent means of results from 10 animals analyzed in duplicate, and error bars
indicate standard deviations. NS, not significant.
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FIG 8 Infection byMVA downregulates expression of costimulatorymolecules, MHC-I, andMHC-II in both infected and noninfected ALDC. ALDC (1 106)
were mock infected (A, D, G, J, andM) or infected with rMVA-Ag85A (B, C, E, F, H, I, K, L, N, and O) using a suboptimalMOI of 0.5 PFU/cell at 4°C for 60min
to allow virus attachment; excess viruswas removed by extensivewashing, and the same number of uninfected autologousALDCwere added. After a 16-h culture
at 37°C, the cells were harvested and stained with propidium iodide and mouse anti-bovine MAbs or isotype control antibodies and cell surface expression was
analyzed by flow cytometry. Events shownwere gated on single FSChigh DEC-205 events. Dot plots are representative of 3 independent experiments. (P) ALDC
were mock infected (gray histogram) or infected (red histogram) with rMVA-GFP and washed as described above. Cells were then cocultured with chicken
embryo fibroblasts (CEF) for 16 h at 37°C. Cells were then harvested, and GFP expression was measured by flow cytometry. The black histograms represent CEF
infected with rMVA-GFP (MOI	 1). The overlay is representative of 3 independent experiments.
5462 jvi.asm.org Journal of Virology
we confirm these results, but we also found that noninfected, PI
ALDC showed downregulation of these molecules (Fig. 8). The
downregulation of CD40 and CD86 was striking; in the case of
MHC-II, the number of MHC-II cells was reduced from99%
to 30% (Fig. 8M and N). Interestingly, MHC class I was not
downregulated in PI ALDC, but in 4% of PI ALDC, this was
downregulated (Fig. 8K). The discrepancy between downregula-
tion of MHC-I and that of MHC-II may provide an indication of
why recombinantMVA induces stronger CD8 than CD4 T cell
responses (4, 67) (Fig. 4 and 7). These data may also indicate why
when poxvirus vectors are used levels of T cell response are gen-
erally lower than in vaccination strategies that utilize replication-
deficient adenovirus vectors (9, 27, 61, 62, 77). At this moment, it
is not known how MVA-infected ALDC affect surface receptor
expression of bystander cells, but our preliminary data indicate
that one ormore soluble factors are involved in this phenomenon.
We then hypothesized that although DC were being killed by
the rMVA, this prompted the generation of chemoattractants pro-
moting migration of noninfected DC toward rMVA-infected DC.
We show that supernatants from rMVA-infected DC promote
migration of noninfected DC and also of T cells and that this
activity is increased in supernatants fromDC infected in the pres-
ence of caspase inhibitors (Fig. 9). Interestingly, most DC that
migrated in our trans-well system were of the phenotype SIRP
CD1b CD21. The biological importance of this is still un-
known. ALDC have an average size of 20 to 30 m, with some
being as large as 45 m, in diameter (our own observations);
however, these are still capable of migrating across a membrane
with pores of 5 or 8 m in diameter. This demonstrates the plas-
ticity and versatility of these cells. Following the migration of DC
toward rMVA-infected DC, we show that the former cells take up
cellular debris generated from the virus infection and subsequent
cell death (Fig. 5 and 6). This cellular debris contains virus-ex-
pressed Ag85A, presumably in addition to other viral antigens.
This phagocytosis requires actin (Fig. 7), and these subcellular
fragments are processed for efficient presentation to CD8 and
CD4 T cells (Fig. 7C and D). These data are supported by the
recent publication of data showing that human peripheral blood
monocytes take up antigens from MVA-infected leukocytes and
thus promoteDCmaturation (24).Mouse andhumanDCmodels
have been used to show that cross-priming is important in induc-
ing T cell responses to recombinant antigens expressed by vaccinia
vectors (26, 46, 69, 70). One important difference between the
data presented here and other reports is thatMVA-induced apop-
tosis is evident within a few hours of infection in DC draining
from the skin but is not observed in in vitro-matured DC until
much later (2, 11, 43). Another difference is that in mouse DC
infected with MVA, the expression of costimulatory molecules
such as CD40 and CD80 is reported to increase or remain un-
changed (26), whereas we observe a fast downregulation of co-
stimulatory molecules (17). This may be due to the origin of the
DC studied and may be of physiological importance.
Our data indicate that following infection of ALDCwithMVA,
these cells secrete or release chemoattractants that induce migra-
FIG 9 MVA-infected ALDC promote chemotaxis of noninfected DC and T cells. Tissue culture supernatants frommock-infected orMVA-infected ALDC (4 or
24 h of infection) were plated in triplicate onto the lower chamber of a trans-well assay plate. FACS-sorted ALDC (1 105) (n	 6) or T cells (n	 5) were then
plated onto the upper chamber of the trans-well assay plate and incubated for 4 h at 37°C. Migration to the lower chamber was measured by flow cytometry. (A)
Dendritic cell migration. (B) T cell migration. (C) Steady-state staining of ALDC showing expression of SIRP and CD21. (D) Dot plot showing the phenotype
of migrated DC. (E) Isotype controls. Dot plots are representative of 6 independent experiments performed in triplicate.
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tion of noninfected DC and T cells (Fig. 8). Although SIRP-
expressing DC represent about 70% of the total population of DC
draining from the skin, only those expressing SIRP migrated
across the membrane toward supernatants from MVA-infected
DC (Fig. 8D). Our laboratory is currently identifying the chemo-
kines secreted by MVA-infected DC.
In the present study, we described a mechanistic view of anti-
gen presentation and the generation of T cell responses to a re-
combinant antigen expressed by modified vaccinia virus Ankara.
We have used the model of cannulation of pseudoafferent lym-
phatic vessels that drain from the skin to obtain dendritic cells
relevant in intramuscular/intradermal/subcutaneous vaccination
protocols. The biological material obtained requires minimal
handling and does not require maturation in vitro, which may
alter its biological functions, and thus provides a more accurate
representation of DC interactions in vivo. However, here were
only report the interaction of ex vivo cells with MVA in vitro, and
so this interaction is investigated under steady-state conditions
andoptimized for the analysis ALDC.One important limitation of
this system is the inability to account for inflammatory stimulus
generated following the delivery of the vaccine through the skin
using a needle, and the so the actual phenotype of cell infected in
vivo and in situ is still unclear. We are currently addressing these
limitations by vaccinating cannulated animals withMVA-GFP, as
we have previously done for adenovirus vectors and the tubercu-
losis vaccine BCG (17, 33).
We provide evidence which indicates that MVA initiates DC
apoptosis upon virus binding or entry via the caspase 8 pathway.
Following virus entry, the caspase 9 pathway is activated and both
pathways contribute to DC apoptosis. After MVA infection, DC
begin to secrete or release chemokines or other cell-attracting
molecules which are yet to be identified and induce migration of
noninfected SIRP DC and T cells toward MVA-infected DC.
Noninfected DC then take up apoptotic bodies and/or cellular
debris and cross-present it to T cells, but there is still only modest
induction of T cell responses. These studies suggest thatmodifying
MVA vectors to reduce their capacity to induce apoptosis of den-
dritic cells is likely to result in enhanced T cell responses and so
improve vaccine efficacy.
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